Actively Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-03-04
6
Participants Needed
7
Research Sites
326 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
CONDITIONS
Official Title
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathogenic or likely pathogenic mutation in BAG3
- Medical history of diagnosis of DCM
- Stable combination of heart failure standard-of-care medications
- Adequate acoustic windows for echocardiography
You will not qualify if you...
- Presence of antibodies to AAV9
- Presence of a pathogenic or likely pathogenic variant in another gene recognized as causing DCM
- Decompensated heart failure
- Other inclusion and exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Research Site
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
Research Site
Boston, Massachusetts, United States, 02115
Actively Recruiting
3
Research Site
Cincinnati, Ohio, United States, 45219
Actively Recruiting
4
Research Site
Portland, Oregon, United States, 97239-3098
Actively Recruiting
5
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
6
Research Site
Barcelona, Spain, 08035
Actively Recruiting
7
Research Site
Majadahonda, Spain, 28222
Actively Recruiting
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here